Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787033 | 0.94 | HRH3 (0.54) | MAOAMAOBCRBNHRH3PRKCI | |
| SCHEMBL29798717 | 0.94 | HRH3 (0.54) | MAOAMAOBCRBNHRH3PRKCI | |
| SCHEMBL26170054 | 0.93 | MAOA (0.54) | MAOAMAOBCRBNHRH3PRKCI | |
| SCHEMBL14158303 | 0.91 | MAOA (0.46) | MAOAMAOBCRBNHRH3PRKCI | |
| SCHEMBL14158305 | 0.91 | MAOA (0.46) | MAOAMAOBCRBNHRH3PRKCI | |
| SCHEMBL3655634 | 0.90 | CRBN (0.49) | MAOAMAOBCRBNHRH3PRKCI | |
| SCHEMBL22713799 | 0.90 | AOC3 (0.56) | MAOAMAOBCRBNHRH3PRKCI | |
| SCHEMBL3651082 | 0.88 | HRH3 (0.67) | MAOAMAOBCRBNHRH3PRKCI | |
| SCHEMBL3657994 | 0.85 | HTR2C (0.52) | MAOAMAOBCRBNHRH3PRKCI | |
| SCHEMBL3655622 | 0.85 | HTR2C (0.52) | MAOAMAOBCRBNHRH3PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810041-B | Halogenated allylamine SSAO/VAP-1 inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-03-11 | — | — | US | disclosed |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-03-11 | — | — | US | disclosed |
| EP-3715341-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2020-09-30 | — | — | EP | disclosed |
| EP-3715341-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2020-09-30 | — | — | EP | disclosed |
| WO-2019101086-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649233-B2 | Halo-allylamine SSAO/VAP-1 inhibitor and use thereof | VAPB, VAPA, ADRA1D | MAOA 1166/4885MAOB 1567/4885CRBN 3898/4885 |
| US-20210070750-A1 | HALO-ALLYLAMINE SSAO/VAP-1 INHIBITOR AND USE THEREOF | VAPB, VAPA, ADRA1D | MAOA 1166/4885MAOB 1567/4885CRBN 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.